31 May 2023
Preliminary Final Report
08 May 2023
LGP wins extended French government tender
01 May 2023
Change of Director's Interest Notice x 4
27 Apr 2023
Quarterly Activities Report & Appendix 4C
24 Apr 2023
Application for quotation of securities - LGP
24 Apr 2023
Application for quotation of securities - LGP
24 Apr 2023
Notification regarding unquoted securities - LGP
24 Apr 2023
Notification of cessation of securities - LGP
17 Apr 2023
First shipment to Ilios Sante in Germany
31 Mar 2023
Change in substantial holding - Tiga Trading Pty Ltd
31 Mar 2023
Cleansing notice
31 Mar 2023
Application for quotation of securities - LGP
24 Mar 2023
Proposed issue of securities - LGP
24 Mar 2023
Proposed issue of securities - LGP
24 Mar 2023
Successful completion of $5 million placement
22 Mar 2023
Trading Halt
22 Mar 2023
Reset Mind Sciences and HIF enter Strategic Alliance
15 Mar 2023
Change in substantial holding - Tiga Trading Pty Ltd
06 Mar 2023
Change of Director's Interest Notice x 4
27 Feb 2023
Cleansing notice
27 Feb 2023
Notification regarding unquoted securities - LGP
27 Feb 2023
Application for quotation of securities - LGP
27 Feb 2023
Notification regarding unquoted securities - LGP
27 Feb 2023
Application for quotation of securities - LGP
15 Feb 2023
Ethics approval granted for psilocybin clinical trial
08 Feb 2023
Ceasing to be a substantial holder
06 Feb 2023
Psilocybin and MDMA down-scheduled
02 Feb 2023
Amended Constitution
31 Jan 2023
Results of Meeting
19 Jan 2023
Notification regarding unquoted securities - LGP
19 Jan 2023
Results of Share Purchase Plan
19 Jan 2023
Application for quotation of securities - LGP
16 Jan 2023
Quarterly Activities Report & Appendix 4C
13 Jan 2023
Notification of cessation of securities - LGP
30 Dec 2022
Change in substantial holding
29 Dec 2022
Letter to Shareholders regarding General Meeting
29 Dec 2022
Notice of General Meeting
19 Dec 2022
Share Purchase Plan offer extended to 16 January 2023
14 Dec 2022
Corrected Appendix 3B
14 Dec 2022
Correction to Announcement and Appendix 3B
02 Dec 2022
Second exclusive supply agreement with Cannamedical
30 Nov 2022
Ethics approval for CBD Phase III clinical trial
30 Nov 2022
Half Yearly Report and Accounts
25 Nov 2022
LGP wins National Export Award for International Health
24 Nov 2022
LGP significantly expands flower portfolio
22 Nov 2022
Change in substantial holding
21 Nov 2022
Letter to Shareholders for Share Purchase Plan
21 Nov 2022
Prospectus
21 Nov 2022
Share Purchase Plan open to eligible shareholders
21 Nov 2022
Update Four 20 Pharma and French trial extension
10 Nov 2022
Change in substantial holding
09 Nov 2022
Cleansing Notice
09 Nov 2022
Application for quotation of securities - LGP
09 Nov 2022
Correction to Appendix 3Y
02 Nov 2022
Proposed issue of securities - LGP
02 Nov 2022
Proposed issue of securities - LGP
02 Nov 2022
LGP announces $4 million placement and $2 million SPP
31 Oct 2022
Quarterly Activities Report & Appendix 4C
31 Oct 2022
Trading Halt
25 Oct 2022
Notice of change in auditor
06 Oct 2022
Notification of cessation of securities - LGP
06 Oct 2022
Change in substantial holding
04 Oct 2022
Exclusive supply agreement with Cannamedical in Germany
28 Sep 2022
TGA advertising infringement notices
06 Sep 2022
Amended Constitution
06 Sep 2022
Change of Director's Interest Notice x 4
06 Sep 2022
Notification regarding unquoted securities - LGP
06 Sep 2022
Application for quotation of securities - LGP
30 Aug 2022
Results of Meeting
29 Aug 2022
AGM Company Update
17 Aug 2022
Notice of Release from Escrow
02 Aug 2022
Notification of cessation of securities - LGP
29 Jul 2022
Letter to Shareholders regarding Annual General Meeting
29 Jul 2022
Notice of Annual General Meeting
27 Jul 2022
Quarterly Activities Report & Appendix 4C
21 Jul 2022
Change of Director's Interest Notice
20 Jul 2022
Notification regarding unquoted securities - LGP
20 Jul 2022
Application for quotation of securities - LGP
20 Jul 2022
Notification of cessation of securities - LGP
20 Jul 2022
Application for quotation of securities - LGP
15 Jul 2022
AGM Date and Closing Date for Director Nominations
13 Jul 2022
Change in substantial holding
12 Jul 2022
LGP signs $2M supply agreement with Ilios Sante
07 Jul 2022
Initial Director's Interest Notice
07 Jul 2022
Former Bayer Regulatory & Quality Director joins LGP Board
01 Jul 2022
Corporate Governance Statement and Appendix 4G
01 Jul 2022
Annual Report to shareholders
06 Jun 2022
Company Update Presentation
31 May 2022
Preliminary Final Report
19 May 2022
Exclusive supply contract for new high-THC strain in Germany
09 May 2022
Cleansing Notice
09 May 2022
Application for quotation of securities - LGP
02 May 2022
LGP Signs Key UK Supply Agreement
29 Apr 2022
Quarterly Activities Report & Appendix 4C
19 Apr 2022
LGP Denmark Signs Major Sales Agreement with Demecan
14 Mar 2022
Change of Director's Interest Notice
07 Mar 2022
Cleansing Notice
07 Mar 2022
Application for quotation of securities - LGP
28 Feb 2022
Half Yearly Report and Accounts
18 Feb 2022
Application for quotation of securities - LGP
18 Feb 2022
LGP Wins Italian Tender
10 Feb 2022
Notice of Release from Escrow
08 Feb 2022
Intention to Demerge Psychedelics Business
02 Feb 2022
Company Update Presentation
27 Jan 2022
Quarterly Activities Report & Appendix 4C
21 Jan 2022
Exclusive Distribution Agreement for LGP Medicines in Greece
19 Jan 2022
Exclusive Cannabis Oils Distribution Agreement in Germany
07 Dec 2021
Application for quotation of securities - LGP
01 Dec 2021
Change in substantial holding
01 Dec 2021
Change in substantial holding
23 Nov 2021
First Registration for Produced Cannabis Medicine in Denmark
22 Nov 2021
Results of Meeting
29 Oct 2021
Jobkeeper Payments FY2021 & FY2020
27 Oct 2021
Investor Presentation
27 Oct 2021
Investor Presentation
27 Oct 2021
Quarterly Activities Report & Appendix 4C
27 Oct 2021
Quarterly Activities Report & Appendix 4C
25 Oct 2021
Presentation at South-West Connect ASX Showcase
15 Oct 2021
Letter to Shareholders regarding Annual General Meeting
15 Oct 2021
Notice of Annual General Meeting
29 Sep 2021
Annual Report to shareholders
29 Sep 2021
Appendix 4G and Corporate Governance Statement
08 Sep 2021
Change of Director's Interest Notice x 2
07 Sep 2021
LGP expands into Psychedelic Medicines
06 Sep 2021
First Danish Shipment to Australia, Key Appointments
06 Sep 2021
AGM Date and Closing Date for Director Nominations
06 Sep 2021
Notification regarding unquoted securities - LGP
31 Aug 2021
Preliminary Final Report
31 Aug 2021
Preliminary Final Report
18 Aug 2021
Change of Director's Interest Notice x 2
17 Aug 2021
Cleansing Notice
17 Aug 2021
Application for quotation of securities - LGP
17 Aug 2021
Notification regarding unquoted securities - LGP
17 Aug 2021
Application for quotation of securities - LGP
17 Aug 2021
Notification regarding unquoted securities - LGP
28 Jul 2021
Quarterly Activities Report & Appendix 4C
19 Jul 2021
Results of Meeting
07 Jul 2021
Change in substantial holding
06 Jul 2021
Becoming a substantial holder
06 Jul 2021
Investor Webinar - Denmark Acquisition
05 Jul 2021
Change in substantial holding
02 Jul 2021
Change in substantial holding - Tiga Trading Pty Ltd
01 Jul 2021
Becoming a substantial holder
01 Jul 2021
Cleansing Notice
01 Jul 2021
Investor Presentation
30 Jun 2021
Application for quotation of securities - LGP
22 Jun 2021
Proposed issue of securities - LGP
22 Jun 2021
Investor Presentation - Denmark acquisition & capital raise
22 Jun 2021
LGP acquires Denmark facility and undertakes share placement
21 Jun 2021
Trading Halt
17 Jun 2021
Exclusive distribution partner - leading Polish pharma group
17 Jun 2021
Letter to Shareholders regarding General Meeting
17 Jun 2021
Notice of General Meeting
15 Jun 2021
Update to Sales and Distribution in Australia and Germany
10 Jun 2021
Becoming a substantial holder - Tiga Trading Pty Ltd
28 May 2021
Results of Meeting
27 May 2021
$2.5m firm order increases expected DEMECAN revenue to $5.7m
28 Apr 2021
Quarterly Activities Report & Appendix 4C
27 Apr 2021
Letter to Shareholders regarding General Meeting
27 Apr 2021
Notice of Extraordinary General Meeting
20 Apr 2021
LGP agrees Danish Distribution Agreement with Balancial
23 Mar 2021
Ceasing to be a substantial holder
15 Mar 2021
Proposed issue of Securities - LGP
15 Mar 2021
Firm purchase order from Demecan and acquisition of land
12 Mar 2021
Change of Director's Interest Notice x 4
12 Mar 2021
Appendix 3G - employee share rights
12 Mar 2021
Cleansing Notice
12 Mar 2021
Appendix 2A - incentive shares & conversion of share rights
12 Mar 2021
Appendix 2A - shares for services
12 Mar 2021
Appendix 2A - conversion of Performance Rights
12 Mar 2021
Appendix 2A - Share Purchase Plan shares
11 Mar 2021
LGP delivers first French shipment
08 Mar 2021
LGP Completes Successful $5 Million SPP
08 Mar 2021
LGP Completes Successful $5 Million SPP
01 Mar 2021
Change in substantial holding
01 Mar 2021
Change in substantial holding
24 Feb 2021
Company Update and Presentation of Half Yearly Results
24 Feb 2021
Half Yearly Report and Accounts
24 Feb 2021
Half Yearly Report and Accounts
18 Feb 2021
Large Scale Cannabis Study Launched
18 Feb 2021
Large Scale Cannabis Study Launched
15 Feb 2021
Appendix 2A - issue of placement shares & cleansing notice
15 Feb 2021
Share Purchase Plan Offer Booklet
09 Feb 2021
Cleansing Notice
09 Feb 2021
Proposed issue of Securities - LGP
09 Feb 2021
LGP secures firm commitments to raise $22 million
08 Feb 2021
Appendix 2A
08 Feb 2021
Appendix 2A - exercise of options
05 Feb 2021
Appendix 2A - release of shares from escrow
05 Feb 2021
LGP exports first commercial shipment to Germany
05 Feb 2021
Trading Halt
29 Jan 2021
Quarterly Activities Report & Appendix 4C
28 Jan 2021
Notice of release from escrow
27 Jan 2021
LGP wins French government tender
12 Jan 2021
Appendix 2A - options exercise & cleansing notice
17 Dec 2020
Change of Director's interest notice x 4
17 Dec 2020
Appendix 2A - options exercise & cleansing notice
17 Dec 2020
Appendix 2A
17 Dec 2020
Appendix 3G
17 Dec 2020
Issue of securities approved at AGM
16 Dec 2020
TGA announces final CBD down-scheduling decision
26 Nov 2020
Results of Annual General Meeting
26 Nov 2020
Company Update to the AGM
19 Nov 2020
First Australian Medicinal Cannabis Oils Exported to Germany
10 Nov 2020
Proposed issue of Securities - LGP
10 Nov 2020
LGP enters strategic partnership with HIF
10 Nov 2020
Trading Halt
10 Nov 2020
Proposed issue of Securities - LGP
27 Oct 2020
Letter to Shareholders regarding Annual General Meeting
27 Oct 2020
Notice of Annual General Meeting
26 Oct 2020
Appendix 2A - Exercise of Options and Cleansing Notice
26 Oct 2020
Quarterly Activities Report & Appendix 4C
21 Oct 2020
Becoming a substantial holder- Tiga Trading Pty Ltd
14 Oct 2020
Little Green Pharma granted GMP Licence
07 Oct 2020
Appendix 2A - Release from Escrow
02 Oct 2020
AGM Date and Closing Date for Director Nominations
30 Sep 2020
Notice of release from escrow
22 Sep 2020
TGA Medicinal Cannabis Post Market Survey
10 Sep 2020
LGP welcomes proposed CBD down-scheduling
04 Sep 2020
Change in substantial holding
31 Aug 2020
Appendix 4G
31 Aug 2020
2020_Annual Report to shareholders
28 Aug 2020
Appendix 2A and Cleansing Notice
28 Aug 2020
Proposed issue of Securities - LGP
26 Aug 2020
Appendix 2A and Cleansing Notice
14 Aug 2020
Appendix 2A - Exercise of Options and Cleansing Notice
03 Aug 2020
Appendix 2A - Release from Escrow
24 Jul 2020
Change in substantial holding
24 Jul 2020
Notice of Release from Escrow
23 Jul 2020
Investor Update Webinar
22 Jul 2020
Investor Presentation
22 Jul 2020
July 2020_Quarterly Activities Report and Appendix 4C
20 Jul 2020
Medicinal Cannabis Permit Granted for Expanded Facility
01 Jul 2020
Appendix 2A - Exercise of Options and Cleansing Notice
01 Jul 2020
Appendix 2A - Release from Escrow
01 Jul 2020
Notice of Release from Escrow
01 Jul 2020
Change of Company Secretary
29 Jun 2020
Strategic Shipment Exported to the UK
28 May 2020
Sales Update - April 2020
13 May 2020
Clarification Statement
11 May 2020
ODC Manufacturing Permit Granted
08 May 2020
Proposed issue of Securities - LGP
30 Apr 2020
Investor Presentation
30 Apr 2020
March 2020_Quarterly Activities Report and Appendix 4C
30 Apr 2020
Virtual Conference
15 Apr 2020
First UK Shipment of Australian Medicinal Cannabis Oil
02 Apr 2020
COVID-19 Business Update
26 Mar 2020
Commissioning of Cultivation Facility Expansion Complete
16 Mar 2020
Investor Presentation
12 Mar 2020
Expanded Medicinal Licence and new Manufacturing Licence
02 Mar 2020
Fourth Medicinal Cannabis Oil Product
28 Feb 2020
Appendix 4D and Half Yearly Report
27 Feb 2020
German Purchase Agreement with Demecan
26 Feb 2020
Becoming a substantial holder - Elixxer Ltd
25 Feb 2020
Becoming a substantial holder - FS
21 Feb 2020
Initial Director's Interest Notice - AC
21 Feb 2020
Initial Director's Interest Notice - FS
21 Feb 2020
Initial Director's Interest Notice - NF
21 Feb 2020
Initial Director's Interest Notice - MLB
19 Feb 2020
Binding Purchase Agreement with UK-Based Astral Health
19 Feb 2020
Confirmation Statements
19 Feb 2020
Top 20 Holders
19 Feb 2020
Distribution Schedule
19 Feb 2020
Securities Trading Policy
19 Feb 2020
Corporate Governance Statement
19 Feb 2020
Employee Incentive Plan Terms
19 Feb 2020
Updated Pro-Forma Balance Sheet
19 Feb 2020
Financial Statements - 30 June 2019
19 Feb 2020
Financial Statements - 30 June 2018
19 Feb 2020
Constitution
19 Feb 2020
Supplementary Prospectus
19 Feb 2020
Prospectus
19 Feb 2020
Appendix 1A and Information Form and Checklist
19 Feb 2020
ASX Notice - Admission to Official List